Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A perioperative study of Safusidenib in patients with IDH1-mutated glioma.

Future oncology (London, England) - 1 Jan 2024

Cain Sarah A, Topp Monique, Rosenthal Mark, Tobler Robert, Freytag Saskia, Best Sarah A, Whittle James R, Drummond Katharine J

Abstract excerpt

This is a single arm, open label perioperative trial to assess the feasibility, pharmacokinetics and pharmacodynamics of treatment with safusidenib following biopsy, and prior to surgical resection in patients with IDH1 mutated glioma who have not received radiation therapy or chemotherapy. Fifteen participants will receive treatment in two parts. First, biopsy followed by one cycle (28 days) of safusidenib, an...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Brain Neoplasms

Share to Glioma

Share to Isocitrate Dehydrogenase

Share to Mutation

Share to Progression-Free Survival

Source

Open in PubMed Open full text

Identifiers

PMID: 39140289
DOI: 10.1080/14796694.2024.2383064
PMCID: PMC11534100

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A perioperative study of Safusidenib in patients with IDH1-mutated glioma.PMID 39140289Read ↗

Perioperative IDH inhibition in treatment-naive IDH-mutant glioma: a pilot trialSemantic proximity Read ↗

Low-grade IDH -mutant gliomas: from standard post-surgical treatments to novel IDH inhibitorsSemantic proximity Read ↗

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade GliomaSemantic proximity Read ↗

The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant glioma.Semantic proximity Read ↗

Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial.Semantic proximity Read ↗

Advances in IDH-mutant glioma management: IDH inhibitors, clinical implications of INDIGO trial, and future perspectives.Semantic proximity Read ↗

The Role of Mutant IDH Inhibitors in the Treatment of Glioma.Semantic proximity Read ↗

Treatment of IDH-mutant glioma in the INDIGO eraSemantic proximity Read ↗

Targeting IDH-Mutant Glioma.Semantic proximity Read ↗

Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial.Semantic proximity Read ↗

IDH inhibition in gliomas: from preclinical models to clinical trialsSemantic proximity Read ↗

Multidisciplinary Management of Isocitrate Dehydrogenase-Mutated Gliomas in a Contemporary Molecularly Defined Era.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.